Navigation path

Pharmaceuticals - Community Register


Community register of orphan medicinal products


Product information

R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1 H -1,4-benzodiazepin-3-yl]-3-(3-methylaminophenyl)urea

EU orphan designation number: EU/3/07/452   
Active ingredient: R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1 H -1,4-benzodiazepin-3-yl]-3-(3-methylaminophenyl)urea
Indication: Treatment of gastric carcinoid
Sponsor: Trio Medicines Ltd
Hammersmith Medicines Research, Cumberland Avenue, London NW10 7EW, United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
19/06/2007 Orphan designation EMEA/OD/014/07 (2007)3028 of 14/06/2007
31/07/2015 Change of address of sponsor